Table 5.
Statistically significant relationships in the assessment of anti-TNF treatment effectiveness.
| Genetic Variants | ||||
|---|---|---|---|---|
| ERAP1 rs2287987 | AA | AG | GG | |
| ESR improvement at 6 months > 50% | (+) | 49 (72.06%) (a) | 15 (48.39%) | 2 (66.67%) |
| (−) | 19 (27.94%) | 16 (51.61%) | 1 (33.33%) | |
| ERAP2 rs2549782 | GG | GT | TT | |
| ESR improvement at 6 months > 50% | (+) | 9 (37.5%) | 31 (64.58%) (b) | 17 (58.62%) |
| (−) | 15 (62.5%) | 17 (35.42%) | 12 (41.38%) | |
| TNFRSF1B rs1061622 | GG | TG | TT | |
| ESR improvement at 6 months > 50% | (+) | 6 (75%) | 27 (79.41%) (c) | 33 (55%) |
| (−) | 2 (25%) | 7 (20.59%) | 27 (45%) | |
| BASDAI 3 months < 3 | (+) | 1 (12.5%) | 19 (55.88%) (d) | 31 (48.44%) |
| (−) | 7 (87.5%) | 15 (44.12%) | 33 (51.56%) | |
| BASDAI improvement 6 months > 75% | (+) | 2 (25%) | 15 (44.12%) (e) | 15 (24.19%) |
| (−) | 6 (75%) | 19 (55.88%) | 47 (75.81%) | |
| FCGR2A rs1801274 | AA | AG | GG | |
| BASDAI 6 months < 2 | (+) | 17 (44.74%) | 24 (48%) | 3 (18.75%) (f) |
| (−) | 21 (55.26%) | 26 (52%) | 13 (81.25%) | |
| BASDAI 6 months < 3 | (+) | 34 (89.47%) | 46 (92%) | 11 (68.75%) (g) |
| (−) | 4 (10.53%) | 4 (8%) | 5 (31.25%) | |
| BASDAI improvement 6 months > 50% | (+) | 34 (89.47%) | 48 (96%) | 11 (68.75%) (h) |
| (−) | 4 (10.53%) | 2 (4%) | 5 (31.25%) | |
(+): the presence of assessed parameter; (−): no parameter assessed; ESR, erythrocyte sedimentation rate; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 3 months, evaluation in the third month of anti-TNF treatment; 6 months, evaluation in the sixth month of anti-TNF treatment. (a) AA vs. AG + GG, p = 0.047, OR = 2.58, 95% CI 1.098–6.26; AA vs. AG, p = 0.026, OR = 2.75, 95% CI 1.11–6.31, AA + GG vs. AG, p = 0.027, OR = 2.72, 95% CI 1.12–6.14; (b) GT + TT vs. GG, p = 0.037, OR = 2.76, 95% CI 1.13–6.72, GT vs. GG, p = 0.044, OR = 3.04, 95% CI 1.09–8.45; (c) TG + GG vs. TT, p = 0.020, OR = 3, 95% CI 1.27–6.9; TG vs. TT, p = 0.025, OR = 3.16, 95% CI 1.18–7.88; TG vs. TT + GG, p = 0.030, OR = 2.87, 95% CI 1.11–7.16; (d) TG vs. GG, p = 0.047, OR = 8.87, 95% CI 1.21–104; (e) TG vs. TT + GG, p = 0.045, OR = 2.46, 95% CI 1.00–6.11; (f) GG vs. AG, p = 0.046, OR = 0.25, 95% CI 0.070–0.979; (g) GG vs. AA + AG, p = 0.028, OR = 0.22, 95% CI 0.062–0.748; GG vs. AG, p = 0.032, OR = 0.19, 95% CI 0.053–0.833; (h) GG vs. AA + AG, p = 0.012, OR = 0.161, 95% CI 0.489–0.594; GG vs. AG, p = 0.007, OR = 0.092, 95% CI 0.017–0.557.